ThromboGenics’ Clinical Data to be Presented at 2016 AAO Meeting in Chicago

11 Oct 2016

Leuven, Belgium – ThromboGenics NV today announces that the company will be attending the upcoming American Academy of Ophthalmology (AAO) 2016 meeting in Chicago, as well as the Subspecialty Day meeting and the Ophthalmology Innovation Summit (OIS @ AAO) preceding the official start of the AAO gathering.

During AAO, a number of communications - posters, presentations and debates - will report on the large amount of ocriplasmin real world clinical data gathered since its first introduction in 2013, as well as on the outcome of the OASIS study, a 2-year randomized, sham-controlled trial evaluating efficacy and safety of ocriplasmin in 220 patients.

'Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial' was published in the latest issue of Ophthalmology, the official AAO Journal.

The AAO meeting, which is taking place in Chicago from 15-18 October, is the largest ophthalmology meeting in the world with more than 24,000 people expected to attend. ThromboGenics data presentations will also be part of the Retina Subspecialty Day meetings which will take place on 14th October and precede AAO.

To date, over 25,000 patients have been treated with ocriplasmin for the treatment of their symptomatic vitreomacular adhesion and/or vitreomacular traction.

ThromboGenics will be exhibiting at AAO (booth #1272) and during the Subspecialty Day meeting (booth #80) where attendees will be welcomed and have the opportunity to discuss the company's next clinical developments in the area of disease modifying compounds for diabetic eye disease.

Dr Patrik De Haes, CEO of ThromboGenics, comments: "The AAO meeting offers a great opportunity for ThromboGenics to showcase our research and commitment to the global retina community it serves. We are always excited to attend AAO and related meetings, as we strive to advance our research and clinical development in diabetic eye disease."

For further information about the AAO meeting please visit